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owReduction of intratumoral brain perfusion by
noninvasive transcranial electrical stimulation
G. Sprugnoli1*, L. Monti2*, L. Lippa3, F. Neri1, L. Mencarelli1, G. Ruffini4, R. Salvador4, G. Oliveri3,
B. Batani3, D. Momi1, A. Cerase2, A. Pascual-Leone5,6, A. Rossi1,7, S. Rossi1,7, E. Santarnecchi1,5†
Malignant brain neoplasms have a poor prognosis despite aggressive treatments. Animal models and evidence
from human bodily tumors reveal that sustained reduction in tumor perfusion via electrical stimulation pro-
motes tumor necrosis, therefore possibly representing a therapeutic option for patients with brain tumors. Here,
we demonstrate that transcranial electrical stimulation (tES) allows to safely and noninvasively reduce intratu-
moral perfusion in humans. Selected patients with glioblastoma or metastasis underwent tES, while perfusion
was assessed using magnetic resonance imaging. Multichannel tES was applied according to personalized bio-
physical modeling, to maximize the induced electrical field over the solid tumor mass. All patients completed
the study and tolerated the procedure without adverse effects, with tES selectively reducing the perfusion of
the solid tumor. Results potentially open the door to noninvasive therapeutic interventions in brain tumors








Glioblastoma (GBM) is the most aggressive and frequent malignant
brain tumor. GBM accounts for more than 60% of adult brain neo-
plasms and affects approximately 10 per 100,000 people worldwide
(1). The prevalence of brainmetastases (MTX) is estimated to be at least
around 9%, with an incidence between 8.3 and 14.3 per 100,000 (2).
MTX originate from primary tumors, with the most common ones be-
ing the lung (19.9%), melanoma (6.9%), kidney (6.5%), breast (5.1%),
and colorectal (1.8%) cancers (2). Despite aggressive treatment
combining neurosurgery, radiation therapy, and chemotherapy (2),
patients with GBM or MTX have a median postdiagnosis survival
window of about 12 months (1).
Electrotherapy (ET) involves the application of a low-intensity direct
electric current into the tumormass bymeans of two ormore platinum
electrodes or indirectly, by electrodes placed in the surrounding tissue
(3). ET offers some promise in the treatment of bodily tumors and can
be combinedwith chemotherapy (i.e., electrochemotherapy), leveraging
its effect by acting on tumor transmembrane permeability and conse-
quently increasing drug concentration in tumor cells (4). Following the
first clinical application in patients with lung cancer, ET has been tested
on other malignant visceral tumors, including hepatocellular carci-
noma, advanced breast cancer, breast hemangioma, and pancreas car-
cinoma (3). In vivo results have confirmed in vitro findings, showing a
reduction of the tumor mass or even prevention of tumor recurrence,
withminimal side effects after ET (3). In a pioneering experiment, Jarm
and colleagues (5) administered low-intensity DC stimulation (0.6 mA)
for 1 hour to subcutaneous fibrosarcoma tumors inmice via two needle
electrodes located 5 mm from the tumor’s margins. Tumor perfusion
(assessed by tissue staining with patent blue violet dye, rubidium ex-traction technique, and noninvasive near-infrared spectroscopy) was
reduced by more than 50%, starting after 15 min of DC stimulation
and lasting for almost 24 hours. Moreover, reduction of perfusion was
followed by a decrease in tumor size 1 day after the intervention. The
decrease in blood flow caused a decrease in tumoral partial oxygen
pressure (pO2), supposedly promoting tumor necrosis (6). Several,
not mutually exclusive, mechanisms for ET effects on tumors have
been proposed: (i) pH alterations near the electrodes due to electrolysis
reaction, (ii) apoptosis, (iii) microembolism, (iv) immunomodula-
tion, (v) toxic derivate of electrochemical reactions, and (vi) vaso-
constriction (3, 6).
Noninvasive application of ET to brain tumors requires technologi-
cal developments. In the current study, we investigated the possibility of
affecting brain tumor perfusion via noninvasive electrical DC brain
stimulation. To assess brain stimulation–induced cerebral blood flow
(CBF) changes, we combined magnetic resonance imaging (MRI)
and noninvasive brain stimulation in patients with GBM and MTX.
In the last two decades, novel forms of noninvasive, transcranial electri-
cal stimulations (tES) have been tested on healthy participants as well as
in patients with various neurological and psychiatric diseases, with the
aim of modulating or restoring cognitive, motor, and psychological
functions (7, 8). In particular, literature on transcranial DC stimulation
(tDCS) suggests that low-intensity electrical stimulation (i.e., <2 mA)
delivered transcranially affects cortical neurons’membrane excitability,
with effects outlasting the stimulation period (7). However, only a few
studies have explored the application of tDCS to modulate brain perfu-
sion in humans (9, 10), with no attempts in patients with brain tumors.
Given the ET findings in bodily tumors, we hypothesized that tDCS
would similarly decrease brain tumorperfusion. T1-weighted (T1w) and
T2-weighted (T2w) MRI sequences were used to manually segment tu-
mors in patients with GBM andMTX, tracing the solid tumor mass, its
necrotic core, and the surrounding tissue affectedby edema (Figs. 1 and2).
Biophysical modeling applied to individual anatomical models ob-
tained from T1w images (11) was used to compare the electrical field
generated by a large set of tDCS electrode montages in each patient
(Fig. 2). Specifically, a genetic algorithm accounting for individual an-
atomical variability and the conductivity of different tumor tissueswas
used to identify a stimulation solution inducing (i) the highest electric
field over the solid tumor while (ii) minimally affecting the rest of the1 of 11









brain (12). Patients underwent tDCS inside the MRI scanner, while
sequences sensitive to CBF, i.e., arterial spin labeling (ASL), and
resting-state functional MRI (rs-fMRI) were acquired before and dur-
ing stimulation. ASL is a noninvasive technique to quantify CBF (i.e.,
perfusion)without the injection of contrasting agents, leveragingmag-
netically labeled arterial blood water protons as an endogenous tracer
(13). fMRI allows to indirectly quantify neuronal activity by detecting
changes in the amount of deoxygenated hemoglobin [expressed by
“blood oxygenation level–dependent” (BOLD) signal (14)]. rs-fMRI
was added as a controlMRI acquisition to verify the selectivity of tDCS
effects on perfusion levels. Considering the neurovascular uncouplingSprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019(NVU) caused by gliomas in peritumoral areas [i.e., edema (15)] and
the absence of healthy neuronal populations able to respond to electrical
stimulation in the tumor region, we hypothesized that tDCS would in-
duce a modulation of perfusion (i.e., CBF) with no changes in BOLD-
related indices [i.e., regional homogeneity (ReHo) and amplitude of
low-frequency fluctuations (ALFFs)] during stimulation. In selected
cases, a tDCS-MRI session after neurosurgery was also carried out,
investigating safety and feasibility of tDCS in the presence of skull
breaches. In those cases, computed tomography (CT) images were used
to carefully model the impact of craniotomy on the electrical field gen-
erated in the cortex (Fig. 3).Fig. 1. Experimental design. (A) Patients underwent a clinical MRI to define and characterize the brain tumor, including standard and gadolinium-enhanced T1w
[CET1w (contrast-enhanced T1w)], T2w, fluid-attenuated inversion recovery (FLAIR), ASL, and resting-state T2-BOLD (blood oxygenation level–dependent) MRI [rs-fMRI
(resting-state functional MRI)] images. Regions of interest (ROIs) were defined by parcellating the solid component and the necrotic core of the tumor (MTX in this
example) using CE T1w sequences and the edema surrounding the tumor by using FLAIR images. (B) Conductivity values were assigned to each ROI as well as to
healthy brain tissue according to existing literature (bottom), and then the E-field distribution of current was calculated (top). (C) The personalized multielectrode
solution maximizing the E-field on the solid-edema interface was selected. The experimental session was planned 3 to 5 days preceding the surgical intervention,
and multichannel tES was performed inside the MRI scanner by means of an MRI-compatible brain stimulation device. The stimulation session included the acquisition
of (i) T1w, FLAIR, ASL, and rs-fMRI sequences before tES; (ii) rs-fMRI and ASL during tES; and (iii) FLAIR images after tES. (D) Roughly 1 week after the presurgery MRI,
patients underwent neurosurgery with subsequent histological classification and immediate postsurgery computerized tomography (CT) acquisition. (E) Last, approx-
imately 1 month after neurosurgery, selected patients underwent a new MRI acquisition and ROI segmentation to perform a second MRI-tES session (F), aimed at
evaluating the safety and feasibility of applying tES after neurosurgery. Additional modeling based on CT scan was performed to account for the effects of skull defects
created by craniotomy (see also Fig. 3). This was crucial to ensure safety and to study/quantify changes in electric field distribution in the presence of skull defects. Note:
All images are presented in neurological convention (right = right).2 of 11











Patients did not experience any clinical or radiological complication
during or after tDCS in either pre- or postsurgical tDCS-MRI sessions.
During postsurgery tDCS, a notably higher amount of stimulation was
estimated to reach the brain/tumor because of current shunting via the
skull breaches (Fig. 3). By creating personalized stimulation models
accounting for shunting, the maximum value of the electric field mag-
nitude was checked against damage threshold levels based on animal
studies, equal to 61 V/m for a current duration of 20 min (7). For all
patients, the maximum electric field (E-field) value never exceeded
1 of 13 of this threshold level, and no adverse effects were observed.
Patients were clinically and MRI monitored throughout the entire
tDCS-MRI session. First, soon after tDCS, an additional sequence [i.e.,
fluid-attenuated inversion recovery (FLAIR)] was performed to rule
out intracranial complications such as enlargement of the peritumoral
edema. Qualitative evaluation of pre- and post-tES FLAIR images did
not reveal any significant changes in the edema extension (Fig. 4).
Second, patients were monitored for about 1 hour after the tDCS-Sprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019MRI before returning to their hospital ward, where standard of care
and clinical monitoring were guaranteed. Third, a questionnaire
investigating potential tES adverse effects was administered at the
end of the tDCS-MRI session (7): Only four patients reported a tin-
gling (consistent with common subjective experience during tES) at
the beginning of stimulation that progressively vanished and did not
produce any discomfort. Last, routine standard-of-careMRI follow-ups
did not show any adverse effects of the intervention. As for patient
survival, two patients (numbers 5 and 8) are currently alive, while the
remaining cohort died after a mean average of 10 months after the first
clinical MRI, in line with the average overall survival (OS) estimated in
previous studies (16).
Perfusion and fMRI changes
Cerebral blood flow
A pattern of decreased perfusion induced by tDCS was observed when
absolute CBF values were corrected for the CBF of contralateral healthy
white matter (WM) (Fig. 5A; see Materials and Methods). In line with
the predicted effect, perfusion in the solid tumor displayed a significantFig. 2. Tumor tracing, modeling, and optimization. (A) MRI images were manually segmented by two independent investigators. Following the Response Assess-
ment in Neuro-Oncology recommendations, the solid part (red) of the tumor (GBM in this example) as well as the necrotic core (blue) were identified on CET1w images.
The edema (green) of the tissue surrounding the tumor was segmented using FLAIR images. In the postsurgery phase, T2 Turbo Spin Echo (TSE) scans were used to
correctly identify the vacuum created by the surgical intervention. ROIs were manually segmented on the corresponding anatomical scan using MRIcro software and 3D
Slicer. ROIs were concentric, with the edema ROI usually including both solid and necrotic parts, while the solid tumor ROI included the necrotic one, such as currently
done for planning of radiation therapy. (B) Top: Conductivity values were assigned to each ROIs as well as to healthy brain tissue according to existing literature: gray
matter (GM) and white matter (WM), cerebrospinal fluid (CSF), skin, and skull. Bottom: A multielectrode solution maximizing stimulation over the edema-solid tumor
interface was identified for each patient, with the corresponding E-field distribution calculated on patients’ head models. Resulting E-field was overlaid onto individual
anatomical T1w scans, showing specificity of the tES solution targeting the solid tumor (C). (D) In detail, the T1w MRI of the participant was segmented into multiple
tissue classes using MARS, SPM-8 segmentation toolbox, and FreeSurfer (left). Models of PITRODE electrodes (cylinders, 1-cm radius) were placed on scalp positions
corresponding to the international 10/10 electroencephalography (EEG) system (green circles, center). A genetic algorithm [Stimweaver (12)] was then used to estimate
the best multielectrode solution among those possible using 32 positions on the scalp (center), with the final personalized tES montage including up to eight electro-
des placed over the hemisphere ipsilateral to the tumor (right). Note: All images are presented in neurological convention (right = right).3 of 11









CBF reduction of −36% (before = 1.784; during = 1.312; t = 4.653,
P = 0.001), ranging from −26% in patients with GBM to −45% in pa-
tients withMTX. CBF changes in the necrotic tumor core were not sig-
nificant (−8.9%, before = 1.272; during = 1.168; t = 1.124, P = 0.294,
ranging from −15% in patients with GBM to −6% in patients with
MTX). Similarly, CBF changes were not significant in the area of peri-
tumoral edema (−5%, before = 1.365; during = 1.299; t= 1.035,P= 0.328,
with −8 and −4% in patients with GBM and MTX, respectively).
Control regions
No significant changes in CBF were observed in any of the control
regions, with a small increase in CBF both ipsilateral (+5.7%,
before = 0.964; during = 1.019; t = −1.375, P = 0.194) and contralateral
(+5.4%, before = 1.064; during = 1.122; t = −0.692, P = 0.502) to the
tumor (Fig. 5B).
rs-fMRI changes
No significant changes were observed with fMRI, neither for ReHo
(necrotic core, before = 0.797; during = 0.778; t = 0.663, P = 0.526; solid
tumor, before = 0.809; during = 0.784; t = 1.585, P = 0.147; edema,
before = 0.825; during = 0.814; t = 1.729, P = 0.118) nor for fractional
ALFF (fALFF) (necrotic core, before = 0.258; during = 0.274; t = −1.642,
P=0.139; solid tumor, before=0.260; during=0.270; t=−1.451,P=0.213;
edema, before = 0.268; during = 0.272; t = −1.141, P = 0.283) (fig. S1), cor-
roborating on the one hand the hypothesized lack of neuronal response
to tES due to NVU (e.g., edema regions) and on the other hand the ab-Sprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019sence of healthy neuronal populations able to respond to tDCS (e.g.,
solid and necrotic parts).DISCUSSION
Traditional applications of tES are aimed atmodifying cortical excitabil-
ity in both the healthy and pathological brains (7). Few studies have in-
vestigated the possibility of using tES to modify brain perfusion, and
none to date has reported the impact of any tES application in patients
with brain tumors. Here, we show that multichannel tDCS in patients
with malignant primary or metastatic brain tumors is safe and feasible
both before and after surgery and also leads to significant tissue-specific
reduction of intratumoral perfusion.
Notably, these results are in line with the reported effects of ET on
bodily tumors, where a strong reduction in tumor perfusion—followed
by a decrease in volume and necrosis—has been shown (3, 5, 6). Given
the safety profile of tDCS, the feasibility of its application in both hos-
pital and home settings, its relatively low cost, and the possibility of its
combination with other drug-based therapies, the present findings
might lead to additional noninvasive therapeutic options for patients
with brain tumors.
Patients with GBM and MTX were selected, considering their high
prevalence and poor prognosis (1, 2, 17). Gliomas’ perfusion is positively
related with the World Health Organization grade and negativelyFig. 3. Postsurgical modeling. (A) Structural MRI and CT images were used to model the impact of tES after surgery (shown: complete resection of a GBM). Ad hoc
ROIs and three-dimensional (3D) renderings were created for both skull breaches and metallic clips that could respectively influence current shunting and affect
electrode positioning. (B) New tissue conductivity values were derived by assigning skull defects a conductivity equal to that of the CSF (left), and the amount of
current (i.e., E-field) shunting through them was estimated (right). (C) A new multielectrode stimulation solution was implemented to maximize stimulation over the
resection borders, showing high spatial specificity and control of induced E-field. (D) In detail, new geometries of the different head tissues (healthy ones and ROIs)
were computed after surgery, leading to a new optimized montage maximizing the current on the surgical borders. Note: All images are presented in neurological
convention (right = right).4 of 11









correlated with survival (18, 19). In particular, for GBM, neoangio-
genesis with increase in vascularization and perfusion are the most
distinctive histopathological features, related to extreme invasive-
ness and aggressive growth (20). Moreover, a pattern of hyperperfu-
sion in GBM strongly correlates with the Ki67 index, a well-defined
marker of cell proliferation (21). Last, CBF and cerebral blood volume
represent validated and reliable markers of tumor progression (22), and
CBF increase detected with ASL is a predictor of a shorter progression-
free survival (PFS) and OS (19). Therefore, the reported tES-induced
reduction in tumor perfusion suggests that repeated applications of
tESmight have a potential disease-modifying impact. Moreover, the in-
dividually tailored brain stimulation solution based onpersonalized bio-
physical modeling fits the precision medicine framework, promoting
the value of individualized treatments.
From a molecular point of view, vascular endothelial growth factor
A (VEGF-A) seems to be the principal mediator of the pathological
neoangiogenesis in GBM, correlating also with clinical outcomes (23).
Considering the importance of inhibiting this specific GBM feature,
antibodies targeting the VEGF pathway [i.e., bevacizumab (BEV)] were
developed and tested.However, controlled phase 3 trials failed to show
a significant effect of BEV on OS in primary GBM (23). Other new
therapies for GBM include the Optune device (NovoTTF-100A system;
Novocure Ltd., Haifa, Israel), recently cleared by the Food and Drug
Administration for the treatment of newly diagnosed and recurrent
GBM.This noninvasive systemdelivers low-intensity alternating current
transcranially to the tumor [tumor-treating fields (TTFs), 200 kHz; field
intensity, >0.7 V/cm at the center of the brain] to inhibit the mitosis ofSprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019malignant cells. For the newly diagnosed GBMs, the interim analysis of
a randomized phase 3 trial showed that TTF combined with standard
chemotherapy (temozolomide) increased the PFS and the OS by about
3 months (24). However, for recurrent GBMs, the phase 3 trial did
not show any significant improvement of PFS or OS (25). Despite the
fact that both TTFs and tES are based on electrical stimulation, funda-
mental technical and conceptual differences exist: (i) TTFsuse alternating
currents oscillating at extraphysiological frequencies—differently from
the DC stimulation used in the present tDCS approach—to impair the
proliferation of malignant cells by reducing mitosis; (ii) tES has a good
safety profile (7), with no adverse effects other than occasional scalp
itching and redness, while a variable but considerable percentage of
patients receiving TTFs (ranging from 19 to 43%) report dermatolog-
ical adverse effects such as dermatitis, erosions, ulcers, and infections (26);
(iii) for TTFs to be effective, patients are required to shave their head and
wear the TTF devices more than 18 hours/day during the treatment
cycle (4weeks), whereas tES offers a light and highly portable alternative
that usually produces neurophysiological effects (e.g., modulation of
corticospinal excitability and cognitive enhancement) even with single,
relatively short (i.e., 30 min) sessions. Future studies should compare
the two techniques, which could be used as complementary interven-
tions possibly leading to additive effects.
Thepostulatedmechanism for the reductionof tumorperfusion caused
by ET on bodily lesions (5, 6) seems compatible with results obtained
with tES applications in brain tumors.Occlusion and vasoconstriction of
the vessels in proximity to the electrodes have been considered the prin-
cipal effects of ET, caused by electrolysis occurring around both theFig. 4. Safety. FLAIR images acquired before and immediately after tES did not show significant changes in the edema, as shown for two representative patients with
GBM at the presurgery (A) as well as postsurgery stimulation sessions (B). Note: Image constrast was manually adjusted to highlight edema borders. All images are
presented in neurological convention (right = right).5 of 11









cathode and the anode (5, 6). However, how ET selectively affects
tumor vessels, leaving the physiological reactivity of vessels of the
healthy surrounding tissue unaltered, is not clear. It is possible that
the altered micro- and macrostructure characterizing tumor vessels
might make themmore susceptible to the effects of electric stimulation.
These include, for example, lack of smooth muscle cells in the walls,
impaired shunts, and higher intercapillary distance in the context of an
overall irregularmicrovascular architecture (3, 27). In addition, the high
conductivity of tumors as compared with healthy brain tissues (28),
partly due to the abundance of vessels (27), might result in a greater
current density inside the tumor. Other mechanisms, such as a possible
tES effect on nitric oxide (NO) synthase, cannot be excluded, consid-
ering that electrical stimulation has been shown tomodify (i.e., increase)
NO synthase activity in animal models with consequent increase in tu-
mor blood flow (29). In vitro and in vivo brain tumormodels need to beSprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019further explored to disentangle the pathophysiological mechanism
underlining tES-induced CBF reduction.
Studies on ET on bodily tumors have shown that the smaller the
tumor, the greater the resulting decrease in perfusion. In line with these
results, we observed the most important CBF decrease in patients with
MTX, representing the smallest lesions inour sample (CBFdecrease:−45%
inMTX versus−26% inGBM).On the other hand, the different histologic
and vascular features ofMTX (30) could explain their higher responsive-
ness to stimulation.However, this hypothesis needs to be tested on a large
sample of patients, also considering different types of brain MTX (i.e.,
colon, breast, and melanoma) and their locations in the cortical mantle,
which can influence the amount of current delivered in the tumor.
The present tES protocol only included a single session of 20 min of
stimulation at a total intensity across all electrodes of <4mA, in linewith
current safety guidelines (7). Stimulation parameters were defined onFig. 5. Perfusion changes. (A) Significant reduction in WM-corrected CBF (wmCBF = normalized CBF) was observed in the solid tumor during stimulation for both
patients with GBM and MTX (−26 and − 45%, respectively; mean decrease = −36%, *P < 0.001), as compared with no changes in the edema (P < 0.328) and necrotic
core (P < 0.294). absCBF, absolute CBF. (B) Control ROIs in the contra- and ipsilateral hemispheres to each tumor did not show significant changes in CBF. Note:
y axis = normalized CBF calculated as: absolute CBF (ml/100 g per minute)/contralateral WM’s CBF (ml/100 g per minute).6 of 11









the basis of animal studies showing the peak in CBF decrease at around
20′ of continuous ET, while extravasated red blood cells were observed
within the lesions—and in many cases, also in the surrounding healthy
tissues—after 1 hour of stimulation (6). This phenomenon has been re-
lated to leakage of tumor vessels induced by electrolysis and impaired
vessel permeability. In addition, the application of single electric pulse to
the same tumor model has been shown to lead to a slower recovery to
baseline perfusion level after repeated stimulation (31), in line with a
similar finding in healthy volunteers receiving multiple tES sessions
during ASL imaging (9).
The analysis of variation in perfusion levels in ipsilateral and contra-
lateral regions of interest (ROIs) confirmed the selectivity of tES effects
and the accuracy of personalized modeling of induced electric fields. A
trend for CBF increase was noticed in the healthy brain tissue in our
patients (as opposed to the decrease observed in the tumor’s ROIs
and compatible with spontaneous brain perfusion fluctuations), sug-
gesting that tES effects were limited to the regions predicted by the bio-
physical modeling.
BOLD imaging sequences (see fig. S1) were included to verify tES
selectivity on perfusion, given the altered neurovascular response
(NVU) observed in the tumoral aswell as the surrounding healthy brain
tissue (15). BOLD-related indices of amplitude and coherence of neu-
rovascular activity (fALFF and ReHo, respectively) did not reveal any
significant change during tES in any of the three tumor-related ROIs.
fALFF,measuring the amplitude of spontaneous low-frequency fluctua-
tions of BOLD signal, is considered an index of regional spontaneous
neuronal activity (SNA), and it had been explored on a variety of psy-
chiatric and neurological conditions (32). ReHo is thought to reflect
coherence of local brain activity and has been associated to abnormal
activities in many clinical conditions as well (33). Recently, ReHo and
ALFF have been explored in relation to the NVU phenomenon in both
patients with brain tumors (34, 35) and in a murine brain tumor model
(15), with results in line with our findings: The lack of changes in ReHo
and fALFF measured in the edema ROI can be related to previously
reported peritumoral NVU observed in gliomas, caused by the tumor
neoangiogenesis interfering with normal surrounding vasculature (15).
On the other hand, we expected no variation in the tumor regions (i.e.,
solid tumor and necrotic core) considering the lack of healthy neuronal
population modifications responding to tES.
The study has some noteworthy limitations. Because of the main
goal of establishing safety and feasibility, the sample was small, and
we included only two patients with MTX originating both from lung
cancer, thus preventing generalization of findings. This also limited
the possibility to control for possible markers of prediction to tES re-
sponse and to investigate potential correlations between changes in per-
fusion and clinical outcome. In addition, future investigations on
preclinical models are needed to address the molecular changes under-
lining the observed modifications in perfusion levels.
In summary, the present findings support the safety and feasibility of
tES in patients with brain tumors, both before and after brain surgery.
Electrical stimulation on bodily tumors seems to enhance the effect of
chemotherapy treatment (27) by increasing the exposure of malignant
cells to chemotherapy, as a consequence of reduced blood flow caused
by vessels’ vasoconstriction. In addition, a recent study (36) has showed
that tES applied on endothelial monolayers [mimicking the healthy
human blood-brain barrier (BBB)] can induce a transient, reversible,
and polarity-dependent increment in water and solute flux. The possi-
bility to increase transport ofmolecules across the BBB (e.g., relevant for
chemotherapy), along with the reduction of tumor perfusion observedSprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019with tES in our patients, opens the possibility of integrating tES with
chemotherapy in conditions where surgery represents the primary ther-
apeutic option, aswell aswhen chemotherapy is the only viable solution.MATERIALS AND METHODS
Sample
During a 9-month period, 50 patients with brain neoplasms, referred to
the Neurosurgery and Neuroradiology Units of the “Santa Maria alle
Scotte” Medical Center of Siena (Italy), agreed to participate in this
study. Only 18 were considered eligible for the study, which had been
previously approved by Local Ethical Committee. Participants were
screened before the experiment by a multidisciplinary team, including
neurologists, radiologists, and neurosurgeons. Inclusion criteria were as
follows: (i) age between 18 and 80 years, (ii) valid written informed con-
sent, (iii) strong clinical and radiological suspicion of primary GBM or
MTX, and (iv) lesion site presumably reachable by noninvasive stimu-
lation (i.e., cortico-subcortical location). The exclusion criteria were as
follows: (i) lesions in deepWM, brain stem, cerebellum, or basal ganglia;
(ii) multiple brain lesions; (iii) concomitant radiochemotherapy due to
the effect of radiotherapy on tumor perfusion that could alter the assess-
ment of tES effects; (iv) severe dilatation of ventricles; and (v) any health
problem or other potential contraindications to undergo the MRI and
experimental procedures. Patients were carefully informed about the
safety of tES as well as about commonly reported adverse/side effects
to ensure informed consent.
After the initial MRI session (Fig. 1A), manual segmentation of the
brain tumor was performed in preparation for the tDCS-MRI session
(Fig. 1B). Three patients developed health complications before the
experimental intervention (thrombocytopenia, status epilepticus, and
severe intracranial hypertension) and were excluded. Rapid worsening
of clinical conditions led to urgent neurosurgical intervention (2 to 3 days
after clinicalMRI) in seven patients who were therefore excluded. Stim-
ulation sessions were conducted in eight patients (mean age, 62.5; SD,
13 years; five males and three females; see Table 1): Six were diagnosed
with primary GBM and two with MTX from lung cancer. Participants
had concomitant neurological conditions: seizures (n = 2), focal neuro-
logical deficits (n= 3), symptoms and signs of endocranial hypertension
(n = 2); cognitive impairment (n = 1). Some patients received cortico-
steroids, levetiracetam, and heparin (n = 3) during the study. Tumors
were located in different brain regions: frontal lobe (n = 4; two left-
sided), parietal lobe (n = 2; one left-sided), and temporal lobe (n = 2;
one left-sided). Histological analyses of patients with MTX classified
their lesions asMTXof adenocarcinoma (immunohistochemical patterns:
patient 2: TTF1+, CK7+, CKPOOL±, P15+, GATA3−; patient 7: CK7+;
TTF1+; p63−; CDX2−; CK20−). For histological data of patients with
GBM, please refer to table S1.
Tumor segmentation
The ROIs for each patient were created on the basis of the presurgical
MRI assessment (Fig. 1), independently by two investigators (G.S. and
L.Mo.). Following the Response Assessment in Neuro-Oncology recom-
mendations, the solid part of the tumor and the necrotic core were iden-
tified on the contrast-enhanced T1w images. One patient withMTXdid
not showmanually identifiable necrosis inside the tumor. The edema in
the tissue surrounding the tumor was segmented using FLAIR images.
In the postsurgery phase, T2 Turbo Spin Echo (TSE) scans were used to
correctly identify the vacuum created by the surgical intervention. ROIs
were manually segmented on the corresponding anatomical scan using7 of 11









MRIcro software (www.mccauslandcenter.sc.edu/crnl/mricro) and 3D
Slicer (www.slicer.org/). As presented in Figs. 1 to 3, ROIs were concen-
tric, with the edemaROI usually including both solid and necrotic parts,
while the solid tumor ROI included the necrotic core, reflecting what is
currently done during radiotherapy planning (37). For the postsurgery
stimulations, CT scans of the skull were used to map the skull defects
caused by the craniotomy on the T1w images used for biophysical
modeling to model the potential shunting of electrical current through
the skull defects. T1w images were also used to create a ROI of the me-
tallic clips on the scalp to optimize a tDCS solution with no electrodes
close to the postsurgical scar (Fig. 3). Resulting ROIs were compared,
and an agreement about the final set ofmasks to be used for biophysical
modeling and neuroradiological analysis was reached by consensus
(G.S. and L.Mo.).
Individual head model generation
Individual head models were performed for each participant by using a
combination of freely available software tools and custom MATLAB
scripts (MathWorks, Natick,MA, USA; www.mathworks.com), follow-
ing a pipeline derived from (11). T1w MRI images of each participant
were segmented into scalp, skull, air, cerebrospinal fluid (CSF), gray
matter (GM), and WM masks using a MARS toolbox and an SPM 8
(www.fil.ion.ucl.ac.uk/spm/) segmentation toolbox (Figs. 2 and 3).
Models of PITRODE PISTIM 3.14-cm2 Ag/AgCl electrodes (Neuro-
electrics, Barcelona, Spain) were placed in the scalp positions correspond-
ing to the international 10/10 electroencephalography (EEG) system.
Finite-element meshes of the head and electrodes were created using
Iso2Mesh, a MATLAB toolbox. The meshes were then imported to
Comsol (Comsol Inc., Burlington,MA,USA; www.comsol.com), where
the E-field calculations were performed. The manually segmented
masks of the edema, necrotic core, and solid tumor were used to define
the mesh nodes that belong to each of these tissues and used to change
the electrical conductivity of the tissues to match that of the lesion. All
healthy brain tissue nodes were assigned electrical conductivity values
appropriate to DC low-frequency electrical currents: 0.330 S/m (scalp),
0.008 S/m (skull), 10−5 S/m (air), 1.790 S/m (CSF), 0.400 S/m (GM), and
0.150 S/m (WM). The conductivity of the necrotic core nodes was set to
that of CSF. The conductivities of the solid tumor and edema nodes
were defined on the basis of the average WM and GM conductivity
values: half of this average conductivity in the solid tumor nodesSprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019(0.138 S/m) and two-thirds higher in the edema nodes (0.458 S/m;
see Figs. 2 and 3 for examples), according to prior similar modeling
work (38). In three participants, a reevaluation was performed after
neurosurgery. Skull defects created by the surgical intervention were
manually segmented on T1w images with the guide of the skull CT
rendering. Head model regions representing skull defects were as-
signed a conductivity equal to that of CSF (Fig. 3).
Stimulation montage optimization
tES is usually performed by means of two relatively big (area = 35 cm2)
rectangular scalp electrodes (7). However, these so-called “bifocal”
montages do not allow for fine targeting of specific cortical regions be-
cause of low spatial resolution of the resulting E-field. In this study, we
optimized a solution based on multiple (up to eight) smaller (area =
p cm2) circular electrodes that, when guided by neuroimaging data,
can be systematically placed on the scalp to maximize the induced
field in the brain over rather small structures, e.g., a brain tumor (12, 39).
To achieve such resolution, structural MRI images (T1w) of each pa-
tient were preprocessed using the ad hoc pipeline described above.
Cortical GM surfaces were obtained and then intersected with the ede-
ma as well as solid and necrotic tumor masks, defining a target region
aimed at maximizing the normal component of the electric field (En)
over the intersection of the edema and solid tumor mask (Fig. 2). This
target regionwas then used as input for a genetic algorithm [Stimweaver
algorithm (12)] comparing multiple multielectrode montages com-
posed by up to eight stimulating electrodes located on any of the 32
positions of the international 10/10 scalp EEG system. Solutions were
found using constrained least-squares minimization to determine the
electrode positions and currents that induced a weighted En-field that
best approximated the weighted target (i.e., the solid tumor). The
desired En-field was set to 0.25 V/m (the positive value indicates that
the target En-field is directed into the cortical surface, thus presumed
to have an excitatory effect) in the target area. Stimulation was per-
formed using PITRODE PISTIM electrodes (cylindrical 1-cm radius,
p cm2 area, Ag/AgCl/gel electrode; www.neuroelectrics.com), with a
maximal current of 2.0mAat any electrode and amaximal total injected
current of 4.0 mA across a maximal number of eight electrodes (Fig. 2).
Stimulation was applied for 20 min in a single session inside the MRI
scanner. These parameters are within the recommended safety param-
eters for tES in humans (7).Table 1. Patients’ data. F, female; L, left; M, male; R, right.Patient Age Gender Lesion Location (lobe, side) Clinical presentation tES session Pharmacological treatment1 46 M GBM Frontal, L Cognitive deficit Pre- and postsurgery Corticosteroids, levetiracetam2 79 F MTX (lung) Temporal, R Seizures Presurgery Corticosteroids, levetiracetam3 67 M GBM Frontoparietal, R Focal neurological deficit Presurgery Corticosteroids, levetiracetam4 77 F MTX (lung) Frontal, R Seizures Presurgery Corticosteroids, levetiracetam5 54 M GBM Frontal, R Endocranial hypertension Presurgery Corticosteroids, levetiracetam, heparin6 45 F GBM Temporal, L Endocranial hypertension Presurgery Corticosteroids, levetiracetam, heparin7 67 M GBM Frontal, L Focal neurological deficit Pre- and postsurgery Corticosteroids, levetiracetam, heparin8 65 M GBM Parietal, L Focal neurological deficit Postsurgery Corticosteroids, levetiracetam8 of 11










Before starting the MRI-tES session, patients were comfortably seated
in a chair, and scalp was gently cleaned with an alcohol solution to im-
prove skin conductivity under the corresponding electrode. An MRI-
compatible brain stimulator was used for the tES session (Starstim 8
system, with a multichannelMRI kit, Neuroelectrics, Barcelona, Spain),
and participants wore the device throughout the entire MRI session.
Conductive rubber electrodes were inserted in circular sponge sockets
with a radius of 1 cm, having the same area (3.14 cm2) as the PITRODE
PISTIM used for the head model generation. The sockets were dipped
into a saline solution to ensure electric conductivity. Participants were
then brought into the MRI scanner, and the electrodes were connected
to theMRI-compatible cables. Electrode impedance was checked before
launching the first MRI sequence; this also served to ensure that parti-
cipants were familiarized with the tES-induced scalp sensations (e.g.,
tingling) before the MRI session. Particular care was taken to minimize
headmotion via cushions and custom-made padding. Participants were
provided with earplugs and were instructed to try to relax and not to
move during the MRI acquisition time.
MRI acquisition
MRI scans were performed on a Siemens Avanto Syngo VB17 scanner
with a 12-channel head coil (Siemens Medical Solutions, Erlangen,
Germany). Pulsed arterial spin-labeled images were acquired using a
PICORE Q2T sequence [TR (repetition time) = 3100 ms, TE (echo
time) = 22ms, TI (inversion time) 1 = 800ms, TI2 = 1600ms, number
of slices=16, thickness=6.3mm,gap=7.8mm, imagingmatrix=84×84,
flip angle = 90°, acquisition duration = 4 min and 45 s]. High-resolution
T1w axial images covering the whole brain were acquired using a 3D-
MPRAGE sequence (TR = 1880 ms, TE = 3.38 ms, TI = 1100 ms, flip
angle = 15°, number of slices = 176, thickness = 1 mm, gap = 0 mm,
imaging matrix = 256 × 256). FLAIR images were acquired with a
sagittal orientation (TR = 5000 ms, TE = 333 ms, TI = 1800 ms, flip
angle = 120°, thickness = 1 mm, number of slices = 176, imaging
matrix = 224 × 256). T2 TSE images were acquired with a coronal ori-
entation (TR = 4310 ms, TE = 151 ms, TI = 1800 ms, flip angle = 150°,
number of slices = 32, thickness = 4mm, number of averages = 2, imaging
matrix = 444 × 448). Functional images were acquired using a standard
echo-planar imaging (EPI) resting state (TR = 2000 ms, TE = 20 ms, flip
angle = 70°, number of slices = 37, thickness = 3.59 mm, gap = 4.64 mm,
imaging matrix = 448 × 448, acquisition duration = 8 min and 36 s). CT
image acquisition was obtained with a BrightSpeed, CT99, GE Hangwei
Medical Systems, GEHealthcare scanner. The x-ray source was composed
of a single-bend scanning electronbeam(120kV, 320mA), andvolumetric
acquisition was based on 96 images (in-plane resolution, 521 × 512;
thickness = 1 to 1.3 mm) acquired by using a field of view of 25.0 cm.
ASL preprocessing
Functional imaging data processing and analyses were performed using
MATLAB R2014a (MathWorks, Natick, MA, USA; www.mathworks.
com), SPM12 (Wellcome Department of Cognitive Neurology, UK;
www.fil.ion.ucl.ac.uk/spm), and ASLtbx (https://cfn.upenn.edu/~zewang/
ASLtbx.php).The first of 91ASL volumeswas used as theM0 image,with
the remaining 90 volumes used as 45 control-label pairs (labeling first).
A six-parameter rigid body motion spatial transformation was used
to align the raw EPI time series. Then, the functional images were co-
registered to the T1w images. The spuriousmotion component caused
by the systematic label/control alternation was regressed out from the
motion parameters before applying the transformation on the images.Sprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019Each tag and control pair was subtracted to create 45 perfusion-
weighted images. These images were used to create quantified maps
of CBF using the software ASLtbx. Specifically, CBF was quantified
as ml/100 g per minute (absolute CBF) using the equation recom-
mended by the ASL white paper (13)
f ¼ DMlR1aexpðwR1aÞ2M0a ½1 expðtR1aÞ
1
where f is the CBF, DM is the difference signal between the control
and label acquisitions, R1a is the longitudinal relaxation rate of blood, t
is the labeling time, w is the postlabeling delay time, a is the labeling
efficiency, l is the blood/tissue water partition coefficient, andM0 is ap-
proximated by the control image intensity. Four-dimensional CBF
images were masked to remove out-of-brain voxels and normalized
to the Montreal Neurological Institute (MNI) template in SPM12.
CBF images were processed using partial volume correction in the na-
tive ASL spaces and subsequently normalized to MNI space using a
linear affine transformation.
CBF-positive values were extracted from the voxels of the three con-
centric ROIs (necrotic core, solid tumor, and edema). The edema and
solid tumor ROIs were obtained by subtraction (i.e., edema − solid
part = real edema defined as “edema” in the manuscript; solid part −
necrotic core = real solid, defined as “solid tumor”), while the necrotic
ROI was kept the same (“necrotic core”). To verify the selectivity and
specificity of the tES effect, we extracted the CBF absolute values from
additional ROIs that did not show any sign of tumor invasion at the
MRI scans in both the contralateral and ipsilateral hemisphere with re-
spect to the lesion (“control ROIs”). Last, following recent guidelines for
CBF analysis, we calculated also the normalized CBF by dividing the
CBF absolute values by the healthy contralateral WM’s CBF (22).
As a control analysis, quantitative evaluation of CBF were also per-
formed by using the automated Olea Sphere 3.0 postprocessing plat-
form integrated in the MRI scan (Olea Medical SA, La Ciotat, France;
www.olea-medical.com). The Bayesian method was applied to motion
corrected images to calculate CBF maps. Given that Olea Sphere is de-
signed for clinical reading of ASL images, the software was not suitable
for additional custom analyses required by the study design (e.g., cor-
rection forCBF values of contralateralWMtissue). CBF values obtained
on this platform were compared with those obtained by the ad hoc
pipeline developed on MATLAB R2014a, SPM12, and ASLtbx. Raw
CBF values were identical for the two pipelines, following the same pre-
processing of T1w and ASL data.
fMRI preprocessing
To control for the selectivity and specificity of stimulation on CBF, ad-
ditional rs-fMRI scans were added to the protocol. ReHo and fALFF
indices were extracted with CONN software (www.conn-toolbox.org/).
ALFF was considered an index of regional SNA, in contrast to the
more classical functional connectivity analysis that provide insight into
interregional interactions between areas. fALFF used the ratio of the
power spectrum of low frequency (0.01 to 0.08 Hz) to that of the entire
frequency range (e.g., 0 to 0.25 Hz for a TR = 2 s) of BOLD signal,
allowing to discriminate the signal from liquor cisterns to cortical re-
gions. On the other hand, regional homogeneity (ReHo) was thought
to reflect neural synchronization of a given voxel with its neighboring
voxels, with higher ReHo value indicating high regional synchroniza-
tion. In the present analysis, ReHowas calculated according to previous
literature calculating the Kendall’s coefficient of concordance of the
time series of a voxel in relation to those of 26 nearest neighbors.9 of 11







Group-level values introduced to the statistical analyses are reported in
Fig. 5. Preprocessed, WM-corrected CBF values acquired before and
during tES were compared using paired t test statistics for the entire
sample (n = 10; 7 before surgery, 3 after surgery), with an a level
of 0.05. The analysis was conducted separately for each ROI, i.e., solid
tumor (surgical border/residual solid tumor for postsurgery analyses),
edema, andnecrotic core. Separate paired t test analyseswere conducted
for ipsilateral/contralateral control regions as well. The samemodel was
used to look at before versus during tES differences in fALFF and ReHo
values extracted from solid tumor, edema, and necrotic core. Given the
small sample size and independence of each analysis, no correction for
multiple comparisons was applied.
Brain surgery and anatomopathological analysis
Approximately 1 week after the first MRI evaluation (Fig. 1), patients
underwent brain neurosurgery. Complete resection (defined as the
resection of more than 98% of a tumor (40)) was performed on two
patients, subtotal resection (defined as the resection between the 50
and 98% of a tumor) on three patients, partial resection (resection of
less the 50% of a tumor) on one patient, and biopsy on the remaining
two patients. There were no intraoperative complications and post-
operative CT scans ruled out postoperative intracranial bleeding, ten-
sion pneumoencephalon, ischemia, or brain swelling. See table S1 and
the “Sample” section for the immunohistochemical findings./advances.sciencemSUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/8/eaau9309/DC1
Fig. S1. rs-fMRI changes.
Table S1. Histological data of patients with GBM. on M
arch 26, 2021
ag.org/REFERENCES AND NOTES
1. D. A. Reardon, K. L. Ligon, E. A. Chiocca, P. Y. Wen, One size should not fit all: Advancing
toward personalized glioblastoma therapy. Discov. Med. 19, 471–477 (2015).
2. M. Valiente, M. S. Ahluwalia, A. Boire, P. K. Brastianos, S. B. Goldberg, E. Q. Lee, E. Le Rhun,
M. Preusser, F. Winkler, R. Soffietti, The evolving landscape of brain metastasis.
Trends Cancer 4, 176–196 (2018).
3. H. M. C. Ciria, M. M. González, L. O. Zamora, L. E. B. Cabrales, G. V. S. González,
L. O. de Oliveira, R. Zanella, A. C. Buzaid, O. Parise, L. M. Brito, C. A. A. Teixeira,
M. das Neves Gomes, G. Moreno, V. F. da Veiga, M. Telló, C. Holandino, Antitumor effects
of electrochemical treatment. Chin. J. Cancer Res. 25, 223–234 (2013).
4. A. Hills, J. Stebbing, Electrotherapy: Enlightening modern medicine. Lancet Oncol. 15,
1060–1061 (2014).
5. T. Jarm, Y. A. B. D. Wickramasinghe, M. Deakin, M. Čemažar, J. Elder, P. Rolfe, G. Sersa,
D. Miklavčič, Blood perfusion of subcutaneous tumours in mice following the application
of low-level direct electric current. Adv. Exp. Med. Biol. 471, 497–506 (1999).
6. T. Jarm, M. Cemazar, F. Steinberg, C. Streffer, G. Sersa, D. Miklavcic, Perturbation of blood
flow as a mechanism of anti-tumour action of direct current electrotherapy. Physiol. Meas.
24, 75–90 (2003).
7. A. Antal, I. Alekseichuk, M. Bikson, J. Brockmöller, A. R. Brunoni, R. Chen, L. G. Cohen,
G. Dowthwaite, J. Ellrich, A. Flöel, F. Fregni, M. S. George, R. Hamilton, J. Haueisen,
C. S. Herrmann, F. C. Hummel, J. P. Lefaucheur, D. Liebetanz, C. K. Loo, C. D. McCaig,
C. Miniussi, P. C. Miranda, V. Moliadze, M. A. Nitsche, R. Nowak, F. Padberg,
A. Pascual-Leone, W. Poppendieck, A. Priori, S. Rossi, P. M. Rossini, J. Rothwell,
M. A. Rueger, G. Ruffini, K. Schellhorn, H. R. Siebner, Y. Ugawa, A. Wexler, U. Ziemann,
M. Hallett, W. Paulus, Low intensity transcranial electric stimulation: Safety, ethical, legal
regulatory and application guidelines. Clin. Neurophysiol. 128, 1774–1809 (2017).
8. E. Santarnecchi, N. R. Polizzotto, M. Godone, F. Giovannelli, M. Feurra, L. Matzen, A. Rossi,
S. Rossi, Frequency-dependent enhancement of fluid intelligence induced by transcranial
oscillatory potentials. Curr. Biol. 23, 1449–1453 (2013).
9. X. Zheng, D. C. Alsop, G. Schlaug, Effects of transcranial direct current stimulation (tDCS)
on human regional cerebral blood flow. Neuroimage 58, 26–33 (2011).Sprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 201910. C. Baeken, J. Remue, M.-A. Vanderhasselt, A. R. Brunoni, S. de Witte, R. Duprat,
E. H. W. Koster, R. de Raedt, G.-R. Wu, Increased left prefrontal brain perfusion after MRI
compatible tDCS attenuates momentary ruminative self-referential thoughts. Brain Stimul.
10, 1088–1095 (2017).
11. P. C. Miranda, A. Mekonnen, R. Salvador, G. Ruffini, The electric field in the cortex during
transcranial current stimulation. Neuroimage 70, 48–58 (2013).
12. G. Ruffini, M. D. Fox, O. Ripolles, P. C. Miranda, A. Pascual-Leone, Optimization of
multifocal transcranial current stimulation for weighted cortical pattern targeting from
realistic modeling of electric fields. Neuroimage 89, 216–225 (2014).
13. D. C. Alsop, J. A. Detre, X. Golay, M. Günther, J. Hendrikse, L. Hernandez-Garcia, H. Lu,
B. J. MacIntosh, L. M. Parkes, M. Smits, M. J. P. van Osch, D. J. J. Wang, E. C. Wong,
G. Zaharchuk, Recommended implementation of arterial spin-labeled perfusion MRI for
clinical applications: A consensus of the ISMRM perfusion study group and the European
consortium for ASL in dementia. Magn. Reson. Med. 73, 102–116 (2015).
14. M. D. Fox, M. A. Halko, M. C. Eldaief, A. Pascual-Leone, Measuring and manipulating brain
connectivity with resting state functional connectivity magnetic resonance imaging
(fcMRI) and transcranial magnetic stimulation (TMS). Neuroimage 62, 2232–2243 (2012).
15. R. W. Pak, D. H. Hadjiabadi, J. Senarathna, S. Agarwal, N. V. Thakor, J. J. Pillai, A. P. Pathak,
Implications of neurovascular uncoupling in functional magnetic resonance imaging
(fMRI) of brain tumors. J. Cereb. Blood Flow Metab. 37, 3475–3487 (2017).
16. G. Minniti, G. Lombardi, S. Paolini, Glioblastoma in elderly patients: Current management
and future perspectives. Cancers (Basel) 11, 336 (2019).
17. N. D. Arvold, D. D. Shi, A. A. Aizer, A. D. Norden, D. A. Reardon, E. Q. Lee, L. Nayak,
I. F. Dunn, A. J. Golby, M. D. Johnson, E. B. Claus, E. A. Chiocca, K. L. Ligon, P. Y. Wen,
B. M. Alexander, Salvage re-irradiation for recurrent high-grade glioma and comparison
to bevacizumab alone. J. Neurooncol. 135, 581–591 (2017).
18. L. S. Hu, J. M. Eschbacher, A. C. Dueck, J. E. Heiserman, S. Liu, J. P. Karis, K. A. Smith,
W. R. Shapiro, D. S. Pinnaduwage, S. W. Coons, P. Nakaji, J. Debbins, B. G. Feuerstein,
L. C. Baxter, Correlations between perfusion MR imaging cerebral blood volume,
microvessel quantification, and clinical outcome using stereotactic analysis in recurrent
high-grade glioma. AJNR Am. J. Neuroradiol. 33, 69–76 (2012).
19. X. J. Qiao, B. M. Ellingson, H. J. Kim, D. J. J. Wang, N. Salamon, M. Linetsky, A. R. Sepahdari,
B. Jiang, J. J. Tian, S. R. Esswein, T. F. Cloughesy, A. Lai, L. Nghiemphu, W. B. Pope, Arterial
spin-labeling perfusion MRI stratifies progression-free survival and correlates with
epidermal growth factor receptor status in glioblastoma. AJNR Am. J. Neuroradiol. 36,
672–677 (2015).
20. N. N. Gatson, E. A. Chiocca, B. Kaur, Anti-angiogenic gene therapy in the treatment of
malignant gliomas. Neurosci. Lett. 527, 62–70 (2012).
21. G. A. Alexiou, A. Zikou, S. Tsiouris, A. Goussia, P. Kosta, A. Papadopoulos, S. Voulgaris,
A. P. Kyritsis, A. D. Fotopoulos, M. I. Argyropoulou, Correlation of diffusion tensor,
dynamic susceptibility contrast MRI and 99mTc-Tetrofosmin brain SPECT with tumour
grade and Ki-67 immunohistochemistry in glioma. Clin. Neurol. Neurosurg. 116, 41–45
(2014).
22. M. Jovanovic, S. Radenkovic, T. Stosic-Opincal, S. Lavrnic, S. Gavrilovic, B. Lazovic-Popovic,
I. Soldatovic, R. Maksimovic, Differentiation between progression and pseudoprogresion
by arterial spin labeling MRI in patients with glioblastoma multiforme. J. BUON 22,
1061–1067 (2017).
23. J. Jeck, R. Kassubek, J. Coburger, S. Edenhofer, S. S. Schönsteiner, A. C. Ludolph, B. Schmitz,
J. Engelke, R. Mayer-Steinacker, J. Lewerenz, L. Bullinger, Bevacizumab in temozolomide
refractory high-grade gliomas: Single-centre experience and review of the literature.
Ther. Adv. Neurol. Disord. 11, 1756285617753597 (2018).
24. R. Stupp, S. Taillibert, A. A. Kanner, S. Kesari, D. M. Steinberg, S. A. Toms, L. P. Taylor,
F. Lieberman, A. Silvani, K. L. Fink, G. H. Barnett, J.-J. Zhu, J. W. Henson, H. H. Engelhard,
T. C. Chen, D. D. Tran, J. Sroubek, N. D. Tran, A. F. Hottinger, J. Landolfi, R. Desai, M. Caroli,
Y. Kew, J. Honnorat, A. Idbaih, E. D. Kirson, U. Weinberg, Y. Palti, M. E. Hegi, Z. Ram,
Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide
alone for Glioblastoma. JAMA 314, 2535–2543 (2015).
25. R. Stupp, E. T. Wong, A. A. Kanner, D. Steinberg, H. Engelhard, V. Heidecke, E. D. Kirson,
S. Taillibert, F. Liebermann, V. Dbalý, Z. Ram, J. L. Villano, N. Rainov, U. Weinberg,
D. Schiff, L. Kunschner, J. Raizer, J. Honnorat, A. Sloan, M. Malkin, J. C. Landolfi, F. Payer,
M. Mehdorn, R. J. Weil, S. C. Pannullo, M. Westphal, M. Smrcka, L. Chin, H. Kostron,
S. Hofer, J. Bruce, R. Cosgrove, N. Paleologous, Y. Palti, P. H. Gutin, NovoTTF-100A versus
physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III
trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).
26. M. M. Mrugala, J. Ruzevick, P. Zlomanczuk, R. V. Lukas, Tumor treating fields in
neuro-oncological practice. Curr. Oncol. Rep. 19, 53 (2017).
27. T. Jarm, M. Cemazar, D. Miklavcic, G. Sersa, Antivascular effects of electrochemotherapy:
Implications in treatment of bleeding metastases. Expert Rev. Anticancer Ther. 10,
729–746 (2014).
28. B. Song, P. Wen, T. Ahfock, Y. Li, Numeric investigation of brain tumor influence on the
current distributions during transcranial direct current stimulation. IEEE Trans. Biomed. Eng.
63, 176–187 (2016).10 of 11






29. B. F. Jordan, P. Sonveaux, O. Feron, V. Grégoire, N. Beghein, B. Gallez, Nitric oxide–
mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles
stimulated by electric pulses. Int. J. Radiat. Oncol. Biol. Phys. 55, 1066–1073 (2003).
30. R. R. Langley, I. J. Fidler, The biology of brain metastasis. Clin. Chem. 59, 180–189 (2013).
31. G. Sersa, M. Cemazar, C. S. Parkins, D. J. Chaplin, Tumour blood flow changes induced by
application of electric pulses. Eur. J. Cancer 35, 672–677 (1999).
32. S. L. Fryer, B. J. Roach, K. Wiley, R. L. Loewy, J. M. Ford, D. H. Mathalon, Reduced amplitude
of low-frequency brain oscillations in the psychosis risk syndrome and early illness
schizophrenia. Neuropsychopharmacology 41, 2388–2398 (2016).
33. T. Wu, X. Long, Y. Zang, L. Wang, M. Hallett, K. Li, P. Chan, Regional homogeneity changes
in patients with Parkinson’s disease. Hum. Brain Mapp. 30, 1502–1510 (2009).
34. S. Agarwal, H. Lu, J. J. Pillai, Value of frequency domain resting-state functional magnetic
resonance imaging metrics amplitude of low-frequency fluctuation and fractional
amplitude of low-frequency fluctuation in the assessment of brain tumor-induced
neurovascular uncoupling. Brain Connect. 7, 382–389 (2017).
35. S. Agarwal, H. I. Sair, J. J. Pillai, The resting-state functional magnetic resonance imaging
regional homogeneity metrics–Kendall’s coefficient of concordance-regional
homogeneity and coherence-regional homogeneity–are valid indicators of tumor-related
neurovascular uncoupling. Brain Connect. 7, 228–235 (2017).
36. L. M. Cancel, K. Arias, M. Bikson, J. M. Tarbell, Direct current stimulation of endothelial
monolayers induces a transient and reversible increase in transport due to the
electroosmotic effect. Sci. Rep. 8, 9265 (2018).
37. S. Fogh, M. Wahl, M. Anwar, D. Haas-Kogan, J. L. Clarke, P. K. Sneed, Standardization and
quality assurance of radiation therapy volumes for adults with high-grade gliomas.
Semin. Radiat. Oncol. 24, 259–264 (2014).
38. P. C. Miranda, A. Mekonnen, R. Salvador, P. J. Basser, Predicting the electric field distribution
in the brain for the treatment of glioblastoma. Phys. Med. Biol. 59, 4137–4147 (2014).
39. G. Ruffini, F. Wendling, R. Sanchez-Todo, E. Santarnecchi, Targeting brain networks with
multichannel transcranial current stimulation (tCS). Curr. Opin. Biomed. Eng. 8, 70–77 (2018).
40. N. Ahmadloo, A.-A. Kani, M. Mohammadianpanah, H. Nasrolahi, S. Omidvari, A. Mosalaei,
M. Ansari, Treatment outcome and prognostic factors of adult glioblastoma multiforme.
J. Egypt Natl. Canc. Inst. 25, 21–30 (2013).Sprugnoli et al., Sci. Adv. 2019;5 : eaau9309 14 August 2019Acknowledgments: We would like to thank the study participants and their families, as well
as the radiology technicians for their support during the MRI acquisitions. Funding: E.S. and
A.P.-L. are partially supported by the BROAD Institute at Harvard-MIT (Boston, MA) via
2016P000351. E.S. and A.P.-L. are partially supported by the Defense Advanced Research
Projects Agency (DARPA) via HR001117S0030. E.S. is supported by the Beth Israel Deaconess
Medical Center (BIDMC) via the Chief Academic Officer (CAO) grant 2017 and by the National
Institute of Aging at NIH via R01-AG060981-01. A.P.-L. is further supported by the Berenson-
Allen Foundation, the Sidney R. Baer Jr. Foundation, grants from the NIH (R01HD069776,
R01NS073601, R21 MH099196, R21 NS082870, R21 NS085491, and R21 HD07616), and Harvard
Catalyst/The Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH,
UL1 RR025758). The content of this paper is solely the responsibility of the authors and does
not necessarily represent the official views of Harvard Catalyst, Harvard University and its
affiliated academic health care centers, the National Institutes of Health, and the Sidney
R. Baer Jr. Foundation. Author contributions: Conceptualization: G.S. and E.S. Methodology:
E.S., G.R., and R.S. Investigation: L.Mo., L.L., F.N., L.Me., G.O., B.B., E.S., and A.C. Software:
D.M., E.S., G.R., and R.S. Formal analysis: E.S. Writing: Original draft, G.S. and E.S. Review and
editing: G.S., E.S., A.P.-L., S.R., and G.R. Resources: G.R., and E.S. Supervision: A.P.-L., A.R., S.R.,
and E.S. Competing interests: G.R. and R.S. work for Neuroelectrics. G.R. is a founder of
Neuroelectrics. A.P.-L. serves on the medical advisory board for Neuroelectrics. The other authors
declare that they have no competing interests. Data and materials availability: All data needed
to evaluate the conclusions in the paper are present in the paper and/or the Supplementary
Materials. Additional data related to this paper may be requested from the authors.
Submitted 30 July 2018
Accepted 10 July 2019
Published 14 August 2019
10.1126/sciadv.aau9309
Citation: G. Sprugnoli, L. Monti, L. Lippa, F. Neri, L. Mencarelli, G. Ruffini, R. Salvador, G. Oliveri,
B. Batani, D. Momi, A. Cerase, A. Pascual-Leone, A. Rossi, S. Rossi, E. Santarnecchi, Reduction of
intratumoral brain perfusion by noninvasive transcranial electrical stimulation. Sci. Adv. 5,





Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation
Pascual-Leone, A. Rossi, S. Rossi and E. Santarnecchi
G. Sprugnoli, L. Monti, L. Lippa, F. Neri, L. Mencarelli, G. Ruffini, R. Salvador, G. Oliveri, B. Batani, D. Momi, A. Cerase, A.
DOI: 10.1126/sciadv.aau9309






This article cites 40 articles, 3 of which you can access for free
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Terms of ServiceUse of this article is subject to the 
 is a registered trademark of AAAS.Science AdvancesYork Avenue NW, Washington, DC 20005. The title 
(ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 NewScience Advances 
License 4.0 (CC BY-NC).
Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial 
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of
 on M
arch 26, 2021
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
